FDA Approves Gilead’s Bixlenvo, the Smallest Once-Daily Single-Pill HIV Regimen

The FDA has approved Bixlenvo, Gilead’s once-daily single-tablet HIV regimen combining bictegravir and lenacapavir — billed as the smallest once-daily single-pill regimen for the disease.

Approved August 27, 2026, it is indicated for virologically suppressed adults, and is notably the first single-tablet option for people on complex regimens who cannot take currently available one-pill treatments.

The population this is actually for

This is the detail that distinguishes Bixlenvo from an incremental convenience improvement.

Most people living with HIV who start treatment today take a single tablet once daily — one of modern medicine’s genuine successes, given that early antiretroviral therapy meant dozens of pills on rigid schedules with severe side effects.

But a meaningful minority cannot use those standard combinations. Some carry resistance accumulated over years of treatment, sometimes dating to eras when regimens were less effective and adherence harder. Some have drug interactions ruling out components, particularly where HIV therapy must coexist with treatment for other conditions. Some cannot tolerate specific agents.

Those patients have remained on multi-pill regimens while everyone else simplified — and until now, no single-tablet option existed for them.

What the two drugs do

Bictegravir is an integrase inhibitor, blocking the enzyme HIV uses to splice its genetic material into the host cell’s DNA. Integrase inhibitors are the backbone of modern first-line therapy, being potent, well tolerated and having a high barrier to resistance.

Lenacapavir is a capsid inhibitor, and it is the more unusual component. The capsid is the protein shell enclosing HIV’s genetic material, and it turns out to be involved at multiple stages of the viral lifecycle rather than acting merely as packaging. Lenacapavir interferes with several of them.

Because capsid inhibition is a mechanistically distinct class, lenacapavir remains active against virus resistant to other drug classes — which is precisely why this combination serves patients whose options had narrowed.

How it is started

Treatment begins with a two-day initiation dose of lenacapavir (Sunlenca), after which patients take only Bixlenvo once daily.

Lenacapavir has an unusually long duration of action — the property that made it viable as a long-acting injectable in other contexts — and the loading approach establishes adequate drug levels before maintenance dosing begins.

The evidence

Approval rests on the Phase 3 ARTISTRY-1 and ARTISTRY-2 studies, presented at CROI earlier in the year, in which Bixlenvo maintained virologic suppression at Week 48 comparable to patients’ prior regimens, and was generally well tolerated with no new safety concerns.

The trial design reflects the population. These are switch studies in patients already virologically suppressed, and the standard is non-inferiority — showing that simplifying does not compromise control. Nobody expects a switch regimen to improve on suppression that is already complete; the question is whether the patient can move to something easier without losing it.

Why pill burden still matters

It would be easy to dismiss tablet count as a lifestyle consideration. In HIV it is a clinical one.

Durable viral control depends on sustained adherence over decades, and adherence degrades with regimen complexity. Missed doses allow the virus to replicate and, critically, to develop resistance — which permanently narrows future options and can be transmitted onward.

For patients already carrying resistance, that risk compounds: they have fewer alternatives remaining, so losing another class of drug matters more. Simplification is therefore protective rather than merely pleasant.

There is also a dimension rarely captured in trials. A pill bottle is a daily reminder of a stigmatised diagnosis, and multi-pill regimens are harder to take discreetly — a real consideration for people who have not disclosed their status.

What is not addressed

The approval covers virologically suppressed adults, so this is a switch option rather than initial therapy. Its value depends on identifying eligible patients, which means clinicians reviewing stable people on complex regimens who may not have been reassessed recently precisely because they are doing well.

Lenacapavir is doing several jobs at once

The same molecule appearing in this tablet has become one of the more versatile agents in HIV medicine, and the reason is its unusual pharmacology.

Lenacapavir was first approved for heavily treatment-experienced patients with multidrug-resistant HIV — the population with the fewest remaining options — precisely because its capsid mechanism is unaffected by resistance to other classes. Its exceptionally long duration of action then made it viable as a long-acting injectable, a formulation with obvious appeal for people who struggle with daily dosing.

Bixlenvo represents a third application: the same drug used as a daily oral component, paired with an integrase inhibitor to build a compact single tablet. A molecule that can serve as salvage therapy, as long-acting prevention or treatment, and as part of a simplification regimen is doing work that would ordinarily require three separate products — and it explains why so much of Gilead’s HIV strategy now runs through this one compound.

Cost and access are not addressed either, and lenacapavir-containing regimens are not inexpensive. As always in HIV, the gap between an approved option and an available one is determined by coverage. Regulatory news, not medical advice.